# A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

> **NCT01297764** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hackensack Meridian Health** · enrollment: 17 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone

## Key facts

- **NCT ID:** NCT01297764
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-04
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297764, "A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01297764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*